Thiolated Chitosan Nanoparticles as a Promising Mucoadhesive Polymer in a Nose-to-Brain Delivery System: A Biodistribution Study in Mice
DOI:
https://doi.org/10.26538/tjnpr/v9i8.39Keywords:
Brain targeting, ex vivo study, in vivo study, Mucoadhesive polymer nanoparticlesAbstract
Delivering therapeutics to the brain is restricted by the blood-brain barrier (BBB). The intranasal route offers a non-invasive alternative to bypass the BBB, but its effectiveness is limited by rapid mucociliary clearance. To overcome this limitation, this study aimed to develop and characterize mucoadhesive thiolated chitosan (TCs) nanoparticles designed to prolong nasal residence time and facilitate nose-to-brain transport. Thiolated chitosan was synthesized, and its chemical modification was confirmed using Fourier-transform infrared spectroscopy (FTIR) and proton nuclear magnetic resonance (1H-NMR). Nanoparticles from both TCs and unmodified chitosan (Cs) were then prepared by ionic gelation, incorporating Nile blue (NB) as a fluorescent probe. The synthesized TCs polymer showed a high degree of thiolation (491.38 ± 5.25 µmol/g). The resulting TCs nanoparticles had a mean particle size of 177.27 ± 4.14 nm, smaller than the Cs nanoparticles (229.03 ± 14.73 nm), with excellent entrapment efficiencies of 93.80% and 94.07%, respectively. In vivo biodistribution studies in male BALB/c mice revealed a prolonged nasal residence time of up to 6 hours for the TCs nanoparticles. Subsequent ex vivo analysis confirmed significantly higher accumulation of TCs nanoparticles in the nasal cavity compared to their Cs counterparts at 2 hours post-administration. Crucially, fluorescent signals originating from the TCs nanoparticle formulation were successfully detected in the brain. These findings demonstrate that thiolated chitosan nanoparticles are a potent mucoadhesive platform. By significantly increasing nasal residence time, this formulation enhances direct nose-to-brain delivery, presenting a promising strategy for transporting therapeutics to the central nervous system.
References
⦁ Jiao Y, Yang L, Wang R, Song G, Fu J, Wang J, Gao N, Wang H. Drug delivery across the blood-brain barrier: A new strategy for the treatment of neurological diseases. Pharmaceutics. 2024; 16(12):1611.
⦁ Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018; 195:44-52.
⦁ Samaridou E, Alonso MJ. Nose-to-brain peptide delivery – The potential of nanotechnology. Bioorg Med Chem. 2018; 26(10):2888-2905.
⦁ Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023; 53:119-152.
⦁ Zahir-Jouzdani F, Wolf JD, Atyabi F, Bernkop-Schnürch A. In situ gelling and mucoadhesive polymers: why do they need each other? Expert Opin Drug Deliv. 2018; 15(10):1007-1019.
⦁ Yu S, Xu X, Feng J, Liu M, Hu K. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. Int J Pharm. 2019; 560:282-293.
⦁ Sunena, Singh K, Mishra DN. Nose to brain delivery of galantamine loaded nanoparticles: in vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliv. 2019; 16(1):51-58.
⦁ Khatoon M, Sohail MF, Shahnaz G, Rehman F, Fakhar-ud-Din, Rehman A, Ullah N, Amin U, Khan GM, Shah KU. Development and evaluation of optimized thiolated chitosan proniosome containing duloxetine for intranasal delivery. AAPS PharmSciTech. 2019; 20(8):288.
⦁ Sadaqa E, Kurniawan F, Mudhakir D. Sodium oleate functionalized simvastatin liposomes: boosting endosomal escape and anticancer efficacy in triple negative breast cancer. Res Pharm Sci. 2025; 20(2):188-206.
⦁ Luo Q, Han Q, Wang Y, Zhang H, Fei Z, Wang Y. Thiolated chitosan: Synthesis, gelling and antibacterial capability. Int J Biol Macromol. 2019; 139:521-530.
⦁ Sadaqa E, Utami RA, Mudhakir D. In vitro cytotoxic and genotoxic effects of Phyllanthus niruri extract loaded chitosan nanoparticles in TM4 cells and their influence on spermatogenesis. Pharmacia. 2024; 71(1):1-14.
⦁ Mudhakir D, Sadaqa E, Permana Z, Mumtazah JE, Zefrina NF, Xeliem JN, Hanum LF, Kurniati NF. Dual-functionalized mesoporous silica nanoparticles for celecoxib delivery: amine grafting and imidazolyl PEI gatekeepers for enhanced loading and controlled release with reduced toxicity. Molecules. 2024; 29(15):3546.
⦁ Baek SH, Hwang EH, Hur GH, Lee YJ, Choe YS, Lee KH, Lee BC. Intranasal administration enhances size-dependent pulmonary phagocytic uptake of poly(lactic-co-glycolic acid) nanoparticles. EJNMMI Radiopharm Chem. 2024; 9(1):4.
⦁ Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull. 2018; 143:155-170.
⦁ Yang YL, Zhang XY, Wu SW, Zhang R, Zhou BL, Zhang XY, Tang L, Tian Y, Men K, Yang L. Enhanced nose-to-brain delivery of siRNA using hyaluronan-enveloped nanomicelles for glioma therapy. J Control Release. 2022; 342:66-80.
⦁ Inamdar NN, Mourya V. Thiolated chitosan preparation, properties, and applications. In: Kim SK, editor. Chitin and Chitosan Derivatives: Advances in Drug Discovery and Future Therapeutics. 1st ed. Boca Raton: CRC Press/Taylor and Francis; 2013. p. 121-145.
⦁ Kousar K, Naseer F, Abduh MS, Kakar S, Gul R, Anjum S, Ahmad T, Niazi MFK, Al-Harrasi A, Al-Rawahi A, Ali B. Green synthesis of hyaluronic acid coated, thiolated chitosan nanoparticles for CD44 targeted delivery and sustained release of Cisplatin in cervical carcinoma. Front Pharmacol. 2023; 14:1270278.
⦁ Arshad M, Sarwar HS, Sarfraz M, Jalil A, Bin Jardan YA, Farooq U, Sohail MF. Cholic acid-grafted thiolated chitosan-enveloped nanoliposomes for enhanced oral bioavailability of azathioprine: In vitro and in vivo evaluation. ACS Omega. 2024; 9:32807-32816.
⦁ Federer C, Kurpiers M, Bernkop-Schnürch A. Thiolated chitosans: A multi-talented class of polymers for various applications. Biomacromolecules. 2021; 22(1):24-56.
⦁ Abbas G, Rasul A, Fakhar-e-Alam M, Saadullah M, Muzammil S, Iqbal O, Atif M, Hanif M, Shah S, Ahmad S, Shafeeq S, Afzal M. Nanoparticles of thiolated chitosan for controlled delivery of moxifloxacin: In-vitro and in-vivo evaluation. J King Saud Univ Sci. 2022; 34(7):102218.
⦁ Zhu X, Su M, Tang S, Wang L, Liang X, Meng F, Hong Y, Xu Z. Synthesis of thiolated chitosan and preparation of nanoparticles with sodium alginate for ocular drug delivery. Mol Vis. 2012; 18:1973-1982.
⦁ Schmidt R, Logan MG, Patty S, Ferracane JL, Pfeifer CS, Kendall AJ. Thiol quantification using colorimetric thiol-disulfide exchange in nonaqueous solvents. ACS Omega. 2023; 8:9356-9363.
⦁ Khalid A, Sarwar HS, Sarfraz M, Sohail MF, Jalil A, Bin Jardan YA, Arshad R, Tahir I, Ahmad Z. Formulation and characterization of thiolated chitosan/polyvinyl acetate based microneedle patch for transdermal delivery of dydrogesterone. Saudi Pharm J. 2023; 31(5):669-677.
⦁
⦁ Chen X, Soria-Carrera H, Zozulia O, Boekhoven J. Suppressing catalyst poisoning in the carbodiimide-fueled reaction cycle. Chem Sci. 2023; 14(44):12653-12660.
⦁ Pratap-Singh A, Guo Y, Baldelli A, Singh A. Mercaptonicotinic acid activated thiolated chitosan (MNA-TG-chitosan) to enable peptide oral delivery by opening cell tight junctions and enhancing transepithelial transport. Sci Rep. 2023; 13(1):17343.
⦁ Sadaqa E, Satrialdi, Kurniawan F, Mudhakir D. Mechanistic insights into endosomal escape by sodium oleate-modified liposomes. Beilstein J Nanotechnol. 2024; 15:1667-1685.
⦁ Shahid N, Erum A, Zaman M, Iqbal MO, Riaz R, Tulain R, Hussain T, Amjad MW, Raja MAG, Farooq U, Aman W. Fabrication of thiolated chitosan based biodegradable nanoparticles of ticagrelor and their pharmacokinetics. Polym Polym Compos. 2022; 30:1-13.
⦁ Kisku A, Nishad A, Agrawal S, Paliwal R, Datusalia AK, Gupta G, Singh SK, Dua K, Sulakhiya K. Recent developments in intranasal drug delivery of nanomedicines for the treatment of neuropsychiatric disorders. Front Med. 2024; 11:1463976
Published
Issue
Section
License
Copyright (c) 2025 Tropical Journal of Natural Product Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
